Crossmark Global Holdings Inc. Has $978,000 Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Crossmark Global Holdings Inc. boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 16.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,487 shares of the company’s stock after buying an additional 1,204 shares during the period. Crossmark Global Holdings Inc.’s holdings in Neurocrine Biosciences were worth $978,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. ProShare Advisors LLC increased its stake in Neurocrine Biosciences by 3.3% in the first quarter. ProShare Advisors LLC now owns 11,829 shares of the company’s stock valued at $1,631,000 after acquiring an additional 383 shares during the period. State Board of Administration of Florida Retirement System grew its stake in shares of Neurocrine Biosciences by 2.0% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 109,446 shares of the company’s stock valued at $15,095,000 after purchasing an additional 2,153 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Neurocrine Biosciences by 34.0% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 55,194 shares of the company’s stock worth $7,612,000 after buying an additional 14,015 shares in the last quarter. Blair William & Co. IL boosted its stake in Neurocrine Biosciences by 5.9% in the 1st quarter. Blair William & Co. IL now owns 8,599 shares of the company’s stock valued at $1,186,000 after buying an additional 481 shares in the last quarter. Finally, Twin Tree Management LP grew its position in Neurocrine Biosciences by 59.4% in the first quarter. Twin Tree Management LP now owns 19,147 shares of the company’s stock valued at $2,641,000 after acquiring an additional 7,136 shares during the period. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Price Performance

Shares of NBIX stock opened at $122.88 on Friday. The stock has a 50-day moving average of $118.53 and a 200-day moving average of $132.88. Neurocrine Biosciences, Inc. has a one year low of $107.84 and a one year high of $157.98. The stock has a market cap of $12.44 billion, a PE ratio of 33.35 and a beta of 0.35.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Oppenheimer boosted their target price on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. StockNews.com downgraded Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Citigroup lifted their price objective on Neurocrine Biosciences from $150.00 to $158.00 and gave the company a “neutral” rating in a research report on Friday, August 2nd. Raymond James restated an “outperform” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Finally, Jefferies Financial Group upped their price target on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a research report on Monday, August 19th. Five research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and an average price target of $163.91.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.